PARLIAMENTARY WRITTEN QUESTION
(5 February 2025)
Question Asked
Asked by:
Adam Dance (Liberal Democrat)
Answer
The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether Brineura (cerliponase alfa) can be recommended for routine NHS funding, taking into account real-world evidence collected during a period of managed access. The NICE and NHS England are actively engaging with BioMarin, as well as other stakeholders in the development of the guidance. These discussions are complex, and given the exceptional nature of this evaluation and the impact on patients and their families, it is essential that they take the necessary time and care to reach the best possible outcome. All parties are also committed to providing updates to stakeholders, notwithstanding the necessity that discussions are undertaken in a confidential setting.
Answered by:
()
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.